Aytu BioScience ( (AYTU) ) has issued an announcement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aytu BioPharma, Inc. announced a proposed settlement in a shareholder derivative lawsuit involving accusations of fiduciary breaches and unjust enrichment by company directors and Armistice Capital. The lawsuit alleges that these parties orchestrated transactions benefiting themselves at the expense of Aytu shareholders. A court hearing is scheduled for January 2025 to determine the fairness of the settlement, which aims to resolve claims and potentially improve corporate governance practices.
See more insights into AYTU stock on TipRanks’ Stock Analysis page.